Literature DB >> 12761724

Postinfectious irritable bowel syndrome.

Robin C Spiller1.   

Abstract

A small but significant subgroup of patients with irritable bowel syndrome (IBS) report a sudden onset of their IBS symptoms after a bout of gastroenteritis. Population-based surveys show that although a history of neurotic and psychologic disorders, pain-related diseases, and gastroenteritis are all risk factors for developing IBS, gastroenteritis is the most potent. More toxigenic organisms increase the risk 11-fold, as does an initial illness lasting more than 3 weeks. Hypochondriasis and adverse life events double the risk for postinfective (PI)-IBS and may account for the increased proportion of women who develop this syndrome. PI-IBS is associated with modest increases in mucosal T lymphocytes and serotonin-containing enteroendocrine cells. Animal models and some preliminary human data suggest this leads to excessive serotonin release from the mucosa. Both the histologic changes and symptoms in humans may last for many years with only 40% recovering over a 6-year follow-up. Celiac disease, microscopic colitis, lactose intolerance, early stage Crohn's disease, and bile salt malabsorption should be excluded, as should colon cancer in those over the age of 45 years or in those with a positive family history. Treatment with Loperamide, low-fiber diets, and bile salt- binding therapy may help some patients. Serotonin antagonists are logical treatments but have yet to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761724     DOI: 10.1016/s0016-5085(03)00324-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  102 in total

1.  Platelet activation in patients with irritable bowel syndrome may reflect a subclinical inflammatory response.

Authors:  A Qasim; H O'Brien; S Sebastian; M O'Sullivan; M Buckley; C O'Moran
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 2.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

3.  How should We Classify and Treat Patients with Functional Gastrointestinal Disorders?

Authors:  John T McLaughlin
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

4.  Enteroendocrine cells: neglected players in gastrointestinal disorders?

Authors:  Gordon W Moran; Fiona C Leslie; Scott E Levison; J Worthington; John T McLaughlin
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

5.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

6.  Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.

Authors:  Robin C Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 7.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

8.  Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice.

Authors:  E F Verdú; P Bercik; M Verma-Gandhu; X-X Huang; P Blennerhassett; W Jackson; Y Mao; L Wang; F Rochat; S M Collins
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

9.  MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.

Authors:  QiQi Zhou; Wiley W Souba; Carlo M Croce; G Nicholas Verne
Journal:  Gut       Date:  2009-12-01       Impact factor: 23.059

10.  Development of colorectal sensitization is associated with increased eosinophils and mast cells in dextran sulfate sodium-treated rats.

Authors:  J M Tobin; L M D Delbridge; R Di Nicolantonio; P Bhathal
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.